BioLineRx Reports Peer-Reviewed Publication of Phase 1/2 Trial Results for Novel Treatment for Non-Surgical Removal of Skin Lesions

By: via Benzinga
BioLineRx Ltd. (NASDAQ: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.